AlzeCure Pharma AB (publ)
OM:ALZCUR Stock Report
AlzeCure Pharma Past Earnings Performance AlzeCure Pharma has been growing earnings at an average annual rate of 9.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually.
Key information Pharmaceuticals Industry Growth 30.5% Revenue growth rate n/a Return on equity -100.4% Net Margin n/a Next Earnings Update 27 Feb 2025
Recent past performance updates AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025 AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024
AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024 Aug 24
AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022 Mar 04 AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021
AlzeCure Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 28, 2021 Aug 25
Show all updates
AlzeCure Pharma AB (publ) Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis Oct 28 AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025
AlzeCure Pharma AB (publ) Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease Oct 01
AlzeCure Pharma AB (publ) Announces New Results from Alzecure's Pain Project TrkA- NAM Presented At the Pain Conference IASP 2024 Aug 07
New minor risk - Shareholder dilution Jun 30
Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain Jun 14
AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors May 16
AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors May 15
Price target decreased by 10% to kr13.00 Apr 28
AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024 Apr 03
New major risk - Market cap size Apr 03
AlzeCure Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 52.77396 million. Mar 28
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference Mar 09
AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's Mar 07
New minor risk - Share price stability Feb 07
AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference Feb 06
AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain Jan 29
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth Dec 02
AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD Oct 26
AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856 Oct 20
Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference Oct 13
AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference Sep 27
AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference Sep 21 AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024
New minor risk - Financial position Aug 25
AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024 Aug 24
AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's Aug 09
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth Jul 20
AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders Jul 12
Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440 May 25
AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board May 20
Forecast to breakeven in 2025 May 09
Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440 Jan 31
AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's Jan 12
Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's Dec 21
AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project Dec 16
Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD Dec 03
Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856 Dec 01
Price target decreased to kr12.00 Nov 16
AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856 Oct 25
Price target decreased to kr12.00 Oct 21
Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely? Oct 12
AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856 Oct 11
AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022 Sep 23
AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial Sep 16 AlzeCure Pharma AB (publ), Annual General Meeting, May 17, 2023
AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856 Aug 31
AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic Jul 06
AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study Jun 30
AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440 Jun 22
Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022 Jun 02
AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440 May 26
AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference Apr 23
AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference Apr 22
Chief Executive Officer recently bought kr163k worth of stock Mar 24
Chief Executive Officer recently bought kr163k worth of stock Mar 24
Chief Financial Officer recently bought kr120k worth of stock Mar 16 Alzecure Pharma AB (Publ) Receives Positive Indicative Clinical Data with Acd856 in Development for Alzheimer's Disease Mar 10
Alzecure Pharma AB (publ) Announces Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA Feb 09
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth? Jan 03
Price target increased to kr21.90 Sep 30
AlzeCure Pharma AB (publ) to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression Aug 13
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth? Jul 12
Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth? Mar 28
AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022 Mar 04 AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021
New 90-day low: kr7.50 Feb 15
Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares Feb 03
New 90-day low: kr8.16 Jan 27
We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate Dec 13
Chief Financial Officer recently bought kr96k worth of stock Dec 08
Chief Financial Officer recently bought kr96k worth of stock Dec 06 AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021
AlzeCure Pharma AB (publ) Receives Approval to Start Clinical Phase I Trial with ACD856 in Alzheimer's Disease Nov 13
New 90-day high: kr11.60 Nov 05
Chief Executive Officer recently bought kr955k worth of stock Oct 21
Alzecure Gets Abstract on the Neurorestore Platform Against Alzheimer's Accepted for Poster Presentation At CTAD Oct 14
AlzeCure Pharma AB Provides Scientific Update on Alzheimer's Disease and the Alzstatin Project Platform Sep 29
Independent Director recently bought kr92k worth of stock Sep 03
New 90-day high - kr9.00 Aug 29
AlzeCure Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 28, 2021 Aug 25
Revenue & Expenses Breakdown
How AlzeCure Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History OM:ALZCUR Revenue, expenses and earnings (SEK Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 0 -36 11 25 30 Jun 24 0 -36 11 26 31 Mar 24 0 -37 11 28 31 Dec 23 0 -37 11 28 30 Sep 23 0 -38 10 29 30 Jun 23 0 -42 10 32 31 Mar 23 0 -53 10 43 31 Dec 22 0 -56 10 46 30 Sep 22 0 -68 10 58 30 Jun 22 0 -73 10 63 31 Mar 22 0 -67 10 57 31 Dec 21 0 -78 11 67 30 Sep 21 0 -73 11 62 30 Jun 21 0 -78 10 68 31 Mar 21 0 -81 10 71 31 Dec 20 0 -71 9 62 30 Sep 20 0 -69 9 61 30 Jun 20 0 -61 8 53 31 Mar 20 0 -53 7 46 31 Dec 19 0 -51 6 45 30 Sep 19 0 -48 5 44 30 Jun 19 -2 -40 4 38 31 Mar 19 -1 -38 4 37 31 Dec 18 0 -36 3 37 30 Sep 18 1 -28 -3 34 31 Dec 17 1 -10 1 10
Quality Earnings: ALZCUR is currently unprofitable.
Growing Profit Margin: ALZCUR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALZCUR is unprofitable, but has reduced losses over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare ALZCUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALZCUR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.8%).
Return on Equity
High ROE: ALZCUR has a negative Return on Equity (-100.41%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}
